RSS-Feed abonnieren
DOI: 10.1055/a-1171-3995
Use of Anticoagulants in Patients with Pulmonary Hypertension
Publikationsverlauf
24. Januar 2020
05. Mai 2020
Publikationsdatum:
29. Juli 2020 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00034925/202003/lookinside/thumbnails/10-1055-a-1171-3995_200003-1.jpg)
Abstract
Since the earliest works on the understanding of different forms of pulmonary hypertension, thrombosis has been involved in the pathophysiology of the disease, both in pulmonary arterial hypertension (PAH) and in chronic thromboembolic pulmonary hypertension (CTEPH). Autopsy and then pathophysiological data paved the way for the use of anticoagulants as a treatment for PAH and CTEPH. In PAH their role has diminished with the advent of specific targeted therapies, but they are still prescribed in more than half of PAH patients, because of concomitant venous thromboembolism or atrial fibrillation. In CTEPH long-term anticoagulant therapy is the cornerstone of the management. The recent development of direct oral anticoagulants (DOACs) raises the question of the best anticoagulation strategy, both in patients with PAH and in patients with CTEPH. In this review, we present an overview of the history of anticoagulants in the management of patients suffering from PAH or CTEPH, an update of the available data on the underlying rationale of their use in these subjects, an alert on the potential risks of using DOACs in these poorly explored situations, and the setting up of dedicated trials to evaluate the best anticoagulant treatment strategies in patients suffering from PAH or CTEPH.
-
References
- 1 Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J 2019; 53 (01) 1802148
- 2 Simonneau G, Montani D, Celermajer DS. , et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53 (01) 1801913
- 3 Abenhaim L, Moride Y, Brenot F. , et al; International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335 (09) 609-616
- 4 Guignabert C, Tu L, Girerd B. , et al. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. Chest 2015; 147 (02) 529-537
- 5 Galiè N, Humbert M, Vachiery J-L. , et al; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (01) 67-119
- 6 Bertoletti L, Ollier E, Duvillard C. , et al. Direct oral anticoagulants: current indications and unmet needs in the treatment of venous thromboembolism. Pharmacol Res 2017; 118: 33-42
- 7 Humbert M, Guignabert C, Bonnet S. , et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 2019; 53 (01) 1801908
- 8 Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70 (04) 580-587
- 9 Christ G, Graf S, Huber-Beckmann R. , et al. Impairment of the plasmin activation system in primary pulmonary hypertension: evidence for gender differences. ThrombHaemost 2001; 86 (02) 557-562
- 10 Huber K, Beckmann R, Frank H, Kneussl M, Mlczoch J, Binder BR. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 1994; 150 (04) 929-933
- 11 Herve P, Humbert M, Sitbon O. , et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001; 22 (03) 451-458
- 12 Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 1998; 12 (06) 1446-1449
- 13 Miniati M, Fiorillo C, Becatti M. , et al. Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic. Am J Respir Crit Care Med 2010; 181 (09) 992-996
- 14 Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327 (02) 76-81
- 15 Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112 (03) 714-721
- 16 Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006; 130 (02) 545-552
- 17 Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 2006; 28 (05) 999-1004
- 18 Humbert M, Sitbon O, Chaouat A. , et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173 (09) 1023-1030
- 19 Robbins IM, Kawut SM, Yung D. , et al. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 27 (03) 578-584
- 20 Aytekin M, Aulak KS, Haserodt S. , et al. Abnormal platelet aggregation in idiopathic pulmonary arterial hypertension: role of nitric oxide. Am J Physiol Lung Cell Mol Physiol 2012; 302 (06) L512-L520
- 21 Kawut SM, Bagiella E, Lederer DJ. , et al; ASA-STAT Study Group. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation 2011; 123 (25) 2985-2993
- 22 Humbert M. The burden of pulmonary hypertension. Eur Respir J 2007; 30 (01) 1-2
- 23 Rich S, Dantzker DR, Ayres SM. , et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107 (02) 216-223
- 24 Humbert M, Sitbon O, Yaïci A. , et al; French Pulmonary Arterial Hypertension Network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36 (03) 549-555
- 25 Benza RL, Miller DP, Gomberg-Maitland M. , et al. Predicting survival in pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 2010; 122 (02) 164-172
- 26 Hoeper MM, Huscher D, Ghofrani HA. , et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013; 168 (02) 871-880
- 27 Mercurio V, Peloquin G, Bourji KI. , et al. Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. Pulm Circ 2018; 8 (02) 2045894018769874
- 28 Bertoletti L, Delavenne X, Montani D. Antithrombotics in pulmonary hypertension: more work needed before we turn to newer agents!. Eur Respir J 2013; 41 (04) 775-777
- 29 Bertoletti L, Mismetti P, Decousus H. Letter by Bertoletti et al regarding article, “Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)”. Circulation 2014; 130 (12) e108
- 30 Gabriel L, Delavenne X, Bedouch P. , et al. Risk of direct oral anticoagulant bioaccumulation in patients with pulmonary hypertension. Respiration 2016; 91 (04) 307-315
- 31 Roldan T, Rios JJ, Villamañan E, Waxman AB. Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers. Pulm Circ 2017; 7 (03) 692-701
- 32 Jensen AS, Idorn L, Thomsen C. , et al. Prevalence of cerebral and pulmonary thrombosis in patients with cyanotic congenital heart disease. Heart 2015; 101 (19) 1540-1546
- 33 Giannakoulas G, Boutsikou M. The Gordian knot of thromboembolism in congenital heart disease. Heart 2015; 101 (19) 1523-1524
- 34 Pepke-Zaba J, Ghofrani H-A, Hoeper MM. Medical management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26 (143) 160107
- 35 Konstantinides SV, Meyer G, Becattini C. , et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
- 36 Sanchez O, Benhamou Y, Bertoletti L. , et al. Recommendations of good practice for the management of thromboembolic venous disease in adults. Short version [in French]. Rev Mal Respir 2019; 36 (02) 249-283
- 37 Grünig E, Benjamin N, Krüger U. , et al. General measures and supportive therapy for pulmonary arterial hypertension: updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272S: 30-36
- 38 Ngian GS, Stevens W, Prior D. , et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2012; 14 (05) R213
- 39 Olsson KM, Delcroix M, Ghofrani HA. , et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129 (01) 57-65
- 40 Preston IR, Roberts KE, Miller DP. , et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation 2015; 132 (25) 2403-2411
- 41 Khan MS, Usman MS, Siddiqi TJ. , et al. Is anticoagulation beneficial in pulmonary arterial hypertension?. Circ Cardiovasc Qual Outcomes 2018; 11 (09) e004757
- 42 Calderone A, Stevens W, Prior D. , et al. Multicentrerandomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. BMJ Open 2016; 6 (12) e011028
- 43 Jose A, Eckman MH, Elwing JM. Anticoagulation in pulmonary arterial hypertension: a decision analysis. Pulm Circ 2019; 9 (04) 2045894019895451
- 44 Żyłkowska J, Kurzyna M, Pietura R. , et al. Recurrent hemoptysis: an emerging life-threatening complication in idiopathic pulmonary arterial hypertension. Chest 2011; 139 (03) 690-693
- 45 Henkens IR, Hazenoot T, Boonstra A, Huisman MV, Vonk-Noordegraaf A. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Eur Respir J 2013; 41 (04) 872-878
- 46 Jujo-Sanada T, Tanabe N, Sakao S. , et al. The anticoagulant effects of warfarin and the bleeding risk associated with its use in patients with chronic thromboembolic pulmonary hypertension at a specialist center in Japan: a retrospective cohort study. Pulm Circ 2017; 7 (03) 684-691
- 47 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J ThrombHaemost 2005; 3 (04) 692-694
- 48 Ogawa A, Matsubara H, Fujio H. , et al. Risk of alveolar hemorrhage in patients with primary pulmonary hypertension--anticoagulation and epoprostenol therapy. Circ J 2005; 69 (02) 216-220
- 49 Nieto JA, Camara T, Gonzalez-Higueras E. , et al; RIETE Investigators. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. ThrombHaemost 2008; 100 (05) 789-796
- 50 Clinicaltrials.gov. Bleeding frequency under anticoagulant treatment in pulmonary hypertension (HEMA-HTP), (NCT02800941), Available at: https://clinicaltrials.gov/ct2/show/NCT02800941?term=anticoagulant&cond=Pulmonary+Arterial+Hypertension&draw=2&rank=1 . Published 2016. Accessed May 25, 2020
- 51 Mai V, Bertoletti L, Cucherat M. , et al. Extended anticoagulation for the secondary prevention of venous thromboembolic events: an updated network meta-analysis. PLoS One 2019; 14 (04) e0214134
- 52 Mai V, Guay CA, Perreault L. , et al. Extended anticoagulation for VTE: a systematic review and meta-analysis. Chest 2019; 155 (06) 1199-1216
- 53 López-López JA, Sterne JAC, Thom HHZ. , et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017; 359: j5058
- 54 Eikelboom JW, Connolly SJ, Brueckmann M. , et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369 (13) 1206-1214
- 55 Pengo V, Denas G, Zoppellaro G. , et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132 (13) 1365-1371
- 56 Spangler ML, Saxena S. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli. Clin Ther 2010; 32 (01) 53-56
- 57 Treiber A, Schneiter R, Häusler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug MetabDispos 2007; 35 (08) 1400-1407
- 58 Walker G, Mandagere A, Dufton C, Venitz J. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. Br J Clin Pharmacol 2009; 67 (05) 527-534
- 59 Roldan T, Villamañán E, Rios JJ, Waxman AB. Assessment of the quality of anticoagulation management in patients with pulmonary arterial hypertension. Thromb Res 2017; 160 (October): 83-90
- 60 Delbeck M, Nickel KF, Perzborn E. , et al. A role for coagulation factor Xa in experimental pulmonary arterial hypertension. Cardiovasc Res 2011; 92 (01) 159-168
- 61 Olsson KM, Wiedenroth CB, Kamp J-C. , et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J 2017; 49 (06) 1602409
- 62 Bunclark K, Newnham M, Chiu YD. , et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J ThrombHaemost 2020; 18 (01) 114-122
- 63 Bertoletti L, Jaïs X, Bezzeghoud S, Delavenne X. Direct oral anticoagulants: Still too early for prime time after pulmonary endarteriectomy?. J ThrombHaemost 2020; 18 (03) 758-759
- 64 Margelidon-Cozzolino V, Hodin S, Jacqueroux E, Delézay O, Bertoletti L, Delavenne X. In vitro assessment of pharmacokinetic drug-drug interactions of direct oral anticoagulants: type 5-phosphodiesterase inhibitors are inhibitors of rivaroxaban and apixaban efflux by P-glycoprotein. J Pharmacol Exp Ther 2018; 365 (03) 519-525
- 65 Jacqueroux E, Mercier C, Margelidon-Cozzolino V, Hodin S, Bertoletti L, Delavenne X. In vitro assessment of P-gp and BCRP transporters-mediated drug-drug interactions of riociguat with direct oral anticoagulants. Fundam Clin Pharmacol 2020; 34 (01) 109-119
- 66 Margelidon-Cozzolino V, Delavenne X, Catella-Chatron J. , et al. Indications and potential pitfalls of anticoagulants in pulmonary hypertension: would DOACs become a better option than VKAs?. Blood Rev 2019; 37: 100579
- 67 Cannon JE, Su L, Kiely DG. , et al. Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the United Kingdom national cohort. Circulation 2016; 133 (18) 1761-1771
- 68 Bunclark K, Ansaripour A, Sheares K, Toshner M. Response to letter to the editor: direct oral anticoagulants in thrombotic antiphospholipid syndrome associated with chronic thromboembolic pulmonary hypertension. J ThrombHaemost 2020; 18 (03) 756-757
- 69 Jiang X, Du Y, Cheng CY. , et al. Antiphospholipid syndrome in chronic thromboembolic pulmonary hypertension: a well-defined subgroup of patients. ThrombHaemost 2019; 119 (09) 1403-1408
- 70 Porres-Aguilar M, Kahn SR, Hirsch AM. Direct oral anticoagulants in thrombotic antiphospholipid syndrome associated with chronic thromboembolic pulmonary hypertension. J ThrombHaemost 2020; 18 (03) 755-756